Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.54 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.46 |
| ▸ | FAAH | O00519 | 4/20 | 0.45 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | MMP9 | P14780 | 2/20 | 0.45 |
| ▸ | MMP8 | P22894 | 2/20 | 0.45 |
| ▸ | MMP12 | P39900 | 2/20 | 0.45 |
| ▸ | MMP14 | P50281 | 2/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21913856 | 0.90 | ALDH1A1 (0.43) | CASP2NAAAMMP2MMP9MMP8 | |
| SCHEMBL21389084 | 0.87 | NOD1 (0.62) | EPHX2SLC6A5NOD1 | |
| SCHEMBL12955866 | 0.87 | CASP2 (0.56) | CASP2NAAAEPHX1FAAHMMP2 | |
| SCHEMBL16409459 | 0.87 | CASP2 (0.51) | CASP2NAAAEPHX1FAAHMMP8 | |
| SCHEMBL23944184 | 0.86 | ALDH1A1 (0.40) | CASP2NAAAMMP2MMP9MMP8 | |
| SCHEMBL29300200 | 0.85 | MMP2 (0.53) | CASP2NAAAEPHX1MMP2MMP9 | |
| SCHEMBL14952664 | 0.84 | ALDH1A1 (0.41) | CASP2NAAAMEN1KMT2A | |
| SCHEMBL24494715 | 0.83 | NOD1 (0.60) | FAAHEPHX2SLC6A5NOD1 | |
| SCHEMBL21389083 | 0.83 | NOD1 (0.53) | EPHX2SLC6A5NOD1 | |
| SCHEMBL21389121 | 0.82 | CASP2 (0.53) | CASP2NAAAEPHX1FAAHDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069299-A1 | Ghrelin analogs | IPSEN PHARMA S.A.S. (FR) | 2010-03-18 | — | — | US | disclosed |
| US-7589058-B2 | Ghrelin analogs | IPSEN PHARMA, S.A.S. (FR) | 2009-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069299-A1 | Ghrelin analogs | GIPR, GLP1R, GHSR | CASP2 2792/4885NAAA 1396/4885EPHX1 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.